Form 4: DexCom Director Kyle Malady Receives RSU Grant

DexCom, Inc. director Kyle Malady was granted 5,575 restricted stock units as part of standard equity compensation.

Summary

• Director Kyle Malady acquired 5,575 restricted stock units (RSUs) of DexCom, Inc. common stock.
• The grant occurred on May 28, 2026.
• The RSUs represent a contingent right to receive one share of common stock per unit upon settlement.
• Following this transaction, the director's total beneficial ownership is 28,242 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified; this is a standard equity grant for a board member.

Risks

• None identified.

Future Outlook

The RSU award is scheduled to vest on the earlier of the one-year anniversary of the grant date (May 28, 2027) or the date of the 2027 Annual Meeting of Stockholders.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term performance and align director interests with those of the shareholders.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation practices for large-cap medical device companies.
• Vesting schedules tied to annual meetings are common practice in the healthcare technology sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity grant.

Next Steps

• Vesting of the RSU award on the earlier of May 28, 2027, or the 2027 Annual Meeting of Stockholders.

Key Dates

Keywords

DexCom, DXCM, Form 4, Insider Trading, Equity Compensation, Director